0001193125-18-054970.txt : 20180223 0001193125-18-054970.hdr.sgml : 20180223 20180223082640 ACCESSION NUMBER: 0001193125-18-054970 CONFORMED SUBMISSION TYPE: 15-12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180223 DATE AS OF CHANGE: 20180223 EFFECTIVENESS DATE: 20180223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sucampo Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001365216 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133929237 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-33609 FILM NUMBER: 18634693 BUSINESS ADDRESS: STREET 1: 805 KING FARM BOULEVARD, SUITE 550 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 3019613400 MAIL ADDRESS: STREET 1: 805 KING FARM BOULEVARD, SUITE 550 CITY: ROCKVILLE STATE: MD ZIP: 20850 15-12B 1 d735658d1512b.htm 15-12B 15-12B

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER

SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION

OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-33609

 

 

SUCAMPO PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

805 King Farm Blvd, Suite 550

Rockville, Maryland 20850

(301) 961-3400

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Class A Common Stock, par value $0.01 per share

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)   ☒
Rule 12g-4(a)(2)   ☐
Rule 12h-3(b)(1)(i)   ☒
Rule 12h-3(b)(1)(ii)   ☐
Rule 15d-6   ☐

Approximate number of holders of record as of the certification or notice date:

Common Stock, par value $0.01 per share: 1

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Sucampo Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: February 23, 2018

    

SUCAMPO PHARMACEUTICALS, INC.

   
   

By:

  

/s/ Kathleen A. Schaefer

     

Name:   Kathleen A. Schaefer

     

Title:    President